相关实验视频
Updated: May 25, 2026
06:04
Ultrasonographic Assessment During Cardiopulmonary Resuscitation
Published on: October 24, 2020
与其他肺炎相比,COVID-19后的心脏事件和程序:国家注册研究研究
Tarjei Øvrebotten1,2, Birgitte Tholin2,3, Kristian Berge4,2
1Department of Cardiology, Division of Medicine, Akershus University Hospital, Lørenskog, Norway tarjeiovrebotten@gmail.com.
Open heart
|February 4, 2025
概括
与其他肺炎相比,住院COVID-19患者患心脏病的风险较低. 关于COVID-19后心脏病风险的这一发现,需要进一步调查潜在的残留混因素.
科学领域:
- 心脏病学 心脏病学
- 传染性疾病 传染性疾病
- 流行病学 流行病学
背景情况:
- COVID-19与心脏病的风险增加有关.
- COVID-19与肺炎的其他原因之间的心脏风险比较仍然不清楚.
研究的目的:
- 为了比较COVID-19住院患者与其他病毒性或细菌性肺炎患者心脏病的发病率和风险比率 (HRs).
主要方法:
- 分析了2020年2月至11月 (COVID-19) 和2018-2019年 (病毒性/细菌性肺炎) 的全国注册数据.
- 心脏结局包括心肌炎,急性心肌梗塞,心房动/动,心力衰竭和缺血性心脏病,通过ICD-10代码确定.
- 考克斯和物流回归模型被用于分析,并根据人口和临床因素进行调整.
主要成果:
- 患有COVID-19的患者 (n=2082) 比患有病毒性 (n=9018) 或细菌性肺炎 (n=29,339) 的患者更年轻,并患有较少的并发症.
- 经过调整后,COVID-19患者与病毒性肺炎 (HR 0.79) 和细菌性肺炎 (HR 0.66) 相比,新发性心脏病的风险较低.
- 当包括复发性心脏事件时,这些发现保持一致.
结论:
- 与其他肺炎相比,住院后9个月内COVID-19住院与新发性心脏病的风险降低有关.
- 尽管对混因子进行了调整,但仍不能排除由未知因素造成的潜在残留混.
相关概念视频
01:30Pneumonia I: Introduction
205
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
205
01:29Pneumonia II: Pathophysiology
211
The pathophysiology of pneumonia involves the following steps:
211
01:30Pneumonia III: Complications and Assessment
150
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
150
01:28Pneumonia IV: Management
296
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
296
01:26Pneumothorax-I
168
A pneumothorax is a condition where air builds up in the space between the lung and the chest wall, causing the lung to collapse. This condition arises when air enters the space between the parietal and visceral pleura, disrupting the negative pressure essential for lung inflation. This can lead to a partial or complete collapse of the lung.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
168
01:27Pneumothorax-II
118
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Clinical Manifestations:
118